Sitaxsentan: An endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 60, Issue 4, 2006, Pages 475-481

  O'Callaghan, D S ^a   Gaine, Sean P ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Endothelin antagonist; Pulmonary arterial hypertension; Sitaxsentan

Indexed keywords

ADENOSINE; AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ILOPROST; MITOGENIC AGENT; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTANOID; SITAXSENTAN; UNIPROST; VASOCONSTRICTOR AGENT;

ARTICLE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG COST; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; EXERCISE TOLERANCE; FUNCTIONAL ASSESSMENT; HUMAN; LIVER TOXICITY; LUNG HEMODYNAMICS; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHINOPHARYNGITIS; SYMPTOMATOLOGY;

HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; RECEPTOR, ENDOTHELIN A; THIOPHENES; TREATMENT OUTCOME;

EID: 33645074912     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00886.x     Document Type: Article

References (63)

1. Barst R, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 40S-47S.
2. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 199; 115: 343-9.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
4. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 5S-12S.
5. Rich S, Brundage BH. High dose calcium channel blocking therapy for primary pulmonary hypertension: Evidence for long term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-41.
6. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
7. Sitbon O, Humbert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-70.
8. Jeffery T, Wanstall JC. Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001; 91: 1-20.
9. Sharma S. Treatment of pulmonary arterial hypertension: A step forward. Chest 2003; 124: 8-11.
10. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin)with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
11. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
12. Olschewski H, Simonneau G, Galie N et al., Aerosolized Iloprost Randomized Study. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.
13. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-7.
14. Saida K, Mitsui Y, Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family: Molecular cloning, expression, and biological activity. J Biol Chem 1989; 264: 14613-6.
15. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
16. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future? J Am Coll Cardiol 2001; 37: 1493-505.
17. Kourembanas S, Marsden PA, McQuillan LP et al. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88: 1054-7.
18. Yoshizumi M, Kurihara H, Sugiyama T et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 1989; 161: 859-64.
19. Wesson D, Simoni J, Green DF. Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells. J Clin Invest 1998; 101: 578-83.
20. Barton M, Shaw S, d'Uscio LV et al. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238: 861-5.
21. Kohno M, Murakawa K, Yokokawa K et al. Production of endothelin by cultured porcine endothelial cells: Modulation by adrenaline. J Hypertens Suppl 1989; 7 (Suppl.): S130 -1.
22. Kanse SM, Takahashi K, Lam H-C et al. Cytokine stimulated endothelin release from endothelial cells. Life Sci 1991; 48: 1379-84.
23. Takeda Y, Miyamori I, Yoneda T et al. Interleukin-2 enhances the release of endothelin-1 from the rat mesenteric artery. Life Sci 1991; 49: 1295-300.
24. Woods M, Bishop-Bailey D, Pepper JR et al. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells. J Cardiovasc Pharmacol 1998; 31 (Suppl. 1): S348-50.
25. D'Orleans-Juste P, LabontéJ, Bkaily G et al. Function of the endothelin B receptor in cardiovascular physiology and pathophysiology. Pharmacol Therapeut 2002; 95: 221-38.
26. Knott P, D'Aprile AC, Henry PJ et al. Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol 1995; 114: 1-3.
27. Pollock D, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 1995; 9: 1196-204.
28. Ohlstein E, Arleth A, Bryan H, Elliott JD, Sung CP. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol 1992; 225: 347-50.
29. De Nucci G, Thomas R, D'Orleans-Juste P et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85: 9797-800.
30. Eddahibi S, Springall D, Mannan M et al. Dilator effect of endothelins in pulmonary circulation: Changes associated with chronic hypoxia. Am J Physiol 1993; 265: L571-80.
31. Alberts GF, Peifley KA, Johns A et al. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269: 10112-10118.
32. Dupuis J, Stewart DJ, Cernacek P et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-84.
33. Wada A, Tsutamoto T, Fukai D et al. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997; 30: 1385-92.
34. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors. J Appl Physiol 1996; 81: 1510-5.
35. Davie N, Haleen SJ, Upton PD et al. ET(A)and ET(B)receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
36. Bauer M, Wilkens H, Langer F et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-6.
37. Langleben D, Dupius J, Langleben I et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 2006: (In press).
38. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-37.
39. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
40. Stewart DJ, Levy RD, Cernacek P et al. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?Ann Intern Med 1991; 114: 464-9.
41. Nootens M, Kaufmann E, Rector T et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581-5.
42. Galie N, Grigioni F, Bacchi-Reggiani L et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996; 26 (Suppl. 1): 273.
43. Miyauchi T, Yorikane R, Sakai S et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993; 73: 887-97.
44. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research "work in progress". Circulation 2000; 102: 2781-91.
45. Langleben D, Barst RJ, Badesch D et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 1999; 99: 3266-71.
46. Farber H, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-65.
47. Channick R, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
48. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896-903.
49. Galie N, Hinderliter AL, Torbicki A et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-6.
50. McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-9.
51. Williamson D, Wallman LL, Jones R et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102: 411-8.
52. Givertz M, Colucci WS, LeJemtel TH et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000; 101: 2922-7.
53. Wu C, Chan MF, Stavros F et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997; 40: 1690-7.
54. Tilton R, Munsch CL, Sherwood SJ et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET (A) receptor antagonist. Pulm Pharmacol Ther 2000; 13: 87-97.
55. Barst R, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Open-Label Pilot Study. Chest 2002; 121: 1860-8.
56. Barst R, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-7.
57. Langleben D, Brock Dixon T, Barst R. STRIDE-1 study group. STRIDE 1: effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004; 44: S80-S84.
58. Galie N, Langleben D, Barst R. STRIDE-2 trial: A placebo-controlled study for sitaxsentan in PAH. Eur Respir J 2005; 26 (Suppl. 49): 476s.
59. Badesch D, Galie N, Langleben D et al. Sitaxsentan improves time to clinical worsening in patients with pulmonary arterial hypertension. Chest 2005; 128 (Suppl.): 160S.
60. Liu C, Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2005; 1: CD004434.
61. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest 2004; 126: 1377-81.
62. Coyne T, Dixon RAF. Warfarin management in pulmonary arterial hypertension is similar among bosentan, placebo and sitaxsentan. Chest 2005; 128 (Suppl.): 366S.
63. Badesch D, Abman SH, Ahearn GS et al., American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (Suppl. 1): 35S-62S.